Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH

    NEXT STORY
    Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
    PREV STORY
    Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio

    TORONTO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) ...

    author_avatar
    NASDAQ Market News

    Emergent BioSolutions to Release Third Quarter 2016 Financial Results and Conduct a Conference Call on November 7, 2016

    GAITHERSBURG, Md., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will release ...

    author_avatar
    NASDAQ Market News

    Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

    author_avatar
    NASDAQ Market News